Skye Historical Cash Flow
| SKYE Stock | USD 2.46 0.20 7.52% |
Analysis of Skye Bioscience, cash flow over time is an excellent tool to project Skye Bioscience, Common future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 10.9 M or Change To Netincome of 983 K as it is a great indicator of Skye Bioscience, ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Skye Bioscience, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Skye Bioscience, Common is a good buy for the upcoming year.
Skye |
About Skye Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Skye balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Skye's non-liquid assets can be easily converted into cash.
Skye Bioscience, Cash Flow Chart
Add Fundamental
Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Skye Bioscience,'s cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Skye Bioscience,'s Other Cashflows From Financing Activities is projected to increase significantly based on the last few years of reporting. The current year's Capital Expenditures is expected to grow to about 23.4 K, whereas Total Cash From Operating Activities is projected to grow to (13.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 593.8K | 6.8M | 23.1M | 24.2M | Depreciation | 34.1K | 115.0K | 124.3K | 130.5K |
Skye Bioscience, cash flow statement Correlations
Click cells to compare fundamentals
Skye Bioscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Skye Bioscience, cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Cashflows From Investing Activities | (19.7K) | (4.4K) | (7.2K) | (90.9K) | (81.8K) | (77.7K) | |
| Other Cashflows From Financing Activities | (80.6K) | 48.5K | 7.0M | 2.0K | 6.6M | 6.9M | |
| Total Cash From Operating Activities | (6.0M) | (6.1M) | (6.5M) | (12.7M) | (14.0M) | (13.3M) | |
| Change To Operating Activities | 185.5K | 161.5K | (147.4K) | 128.3K | 147.6K | 154.9K | |
| End Period Cash Flow | 1.8M | 2.5M | 9.0M | 1.2M | 10.3M | 10.9M | |
| Change To Netincome | 15.1M | (8.0M) | (133.5K) | 772.4K | 695.2K | 983.0K | |
| Change To Liabilities | (85.3K) | 134.2K | 241.6K | 518.6K | 596.4K | 626.3K | |
| Investments | 0.0 | (7.2K) | (90.9K) | 5.2M | 6.6M | 6.9M | |
| Change In Cash | (23.4K) | 639.5K | 6.5M | (7.7M) | 9.1M | 9.5M | |
| Free Cash Flow | (6.0M) | (6.1M) | (6.6M) | (12.8M) | (14.0M) | (13.3M) | |
| Change In Working Capital | 295.7K | 94.2K | 646.9K | (761.9K) | (469.3K) | (445.8K) | |
| Begin Period Cash Flow | 1.9M | 1.8M | 2.5M | 9.0M | 1.2M | 1.2M | |
| Depreciation | 1.5K | 1.9K | 34.1K | 115.0K | 124.3K | 130.5K | |
| Other Non Cash Items | 629.3K | 544.0K | 593.8K | 6.8M | 23.1M | 24.2M | |
| Net Income | 1.1M | (6.6M) | (8.5M) | (19.5M) | (37.6M) | (35.8M) | |
| Total Cash From Financing Activities | 6.0M | 6.7M | 13.1M | (208.8K) | 16.4M | 17.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.